Literature Collection

Magnifying Glass
Collection Insights

13K+

References

11K+

Articles

1700+

Grey Literature

4800+

Opioids & SU

The Literature Collection contains over 13,000 references for published and grey literature on the integration of behavioral health and primary care. Learn More

Use the Search feature below to find references for your terms across the entire Literature Collection, or limit your searches by Authors, Keywords, or Titles and by Year, Type, or Topic. View your search results as displayed, or use the options to: Show more references per page; Sort references by Title or Date; and Refine your search criteria. Expand an individual reference to View Details. Full-text access to the literature may be available through a link to PubMed, a DOI, or a URL. References may also be exported for use in bibliographic software (e.g., EndNote, RefWorks, Zotero).

Enter Search Term(s)
Year
Sort by
Order
Show
13393 Results
7941
Naloxone distribution and possession following a large‐scale naloxone programme
Type: Journal Article
Authors: Desiree Madah‐Amiri, Linn Gjersing, Thomas Clausen
Year: 2019
Topic(s):
Education & Workforce See topic collection
,
Opioids & Substance Use See topic collection
7942
Naloxone Effectiveness: A Systematic Review
Type: Journal Article
Authors: L. Chimbar, Y. Moleta
Year: 2018
Publication Place: United States
Abstract: PURPOSE: Opioid abuse and overdose is a public health concern as it relates to increased morbidity and mortality. This systematic review focuses on the application of take-home naloxone programs and its association with decreased mortality among those who abuse opioids. Take-home naloxone programs consist of distributed naloxone kits and corresponding education of overdose recognition. The purpose of this systematic review was to determine if programs that supply take-home naloxone are effective in preventing fatal overdoses among those who abuse opioids. METHODS: A systematic search was conducted in Academic Search Complete, CINHAL, MEDLINE, PsychINFO, and SocINDEX. The key words searched were "programs," "take-home kits," "Narcan," "Naloxone," and "mortality." On the basis of the predefined inclusion and exclusion criteria, nine studies were found for inclusion. RESULTS: Study results were then synthesized, qualitatively, and within the current research, there is overwhelming support of take-home naloxone programs being effective in preventing fatal opioid overdoses. A significant limitation of this systematic review is the lack of randomized controlled trials as it is viewed as unethical withholding a known lifesaving medication from an at-risk population. PRACTICE IMPLICATIONS: On the basis of the most current evidence, there is overwhelming support of take-home naloxone programs associated with decreased mortality among those who abuse opioids. As a result, there is an implication for a practice change that take-home naloxone programs should be more widely implemented throughout communities as a method of decreasing mortality associated with opioid overdoses. It is recommended that further research is done examining the cost-effectiveness of these programs.
Topic(s):
Opioids & Substance Use See topic collection
7943
Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings
Type: Journal Article
Authors: A. M. Bailey, D. P. Wermeling
Year: 2014
Publication Place: United States
Abstract: BACKGROUND: Deaths related to opioid overdose have increased in the past decade. Community-based pharmacy practitioners have worked toward overcoming logistic and cultural barriers to make naloxone distribution for overdose prevention a standard and accepted practice. OBJECTIVE: To describe outpatient naloxone dispensing practices, including methods by which practitioners implement dispensing programs, prescribing patterns that include targeted patient populations, barriers to successful implementation, and methods for patient education. METHODS: Interviews were conducted with providers to obtain insight into the practice of dispensing naloxone. Practitioners were based in community pharmacies or clinics in large metropolitan cities across the country. RESULTS: It was found that 33% of participating pharmacists practice in a community-pharmacy setting, and 67% practice within an outpatient clinic-based location. Dispensing naloxone begins by identifying patient groups that would benefit from access to the antidote. These include licit users of high-dose prescription opioids (50%) or injection drug users and abusers of prescription medications (83%). Patients were identified through prescription records or provider screening tools. Dispensing naloxone required a provider's prescription in 5 of the 6 locations identified. Only 1 pharmacy was able to exercise pharmacist prescriptive authority within their practice. CONCLUSION: Outpatient administration of intramuscular and intranasal naloxone represents a means of preventing opioid-related deaths. Pharmacists can play a vital role in contacting providers, provision of products, education of patients and providers, and dissemination of information throughout the community. Preventing opioid overdose-related deaths should become a major focus of the pharmacy profession.
Topic(s):
Opioids & Substance Use See topic collection
,
Education & Workforce See topic collection
7944
Naloxone for Opioid Overdose: Comment
Type: Journal Article
Authors: B. L. Milas, A. J. Varon
Year: 2024
Topic(s):
Opioids & Substance Use See topic collection
Reference Links:       
7945
Naloxone for Opioid Overdose: Comment
Type: Journal Article
Authors: G. G. Pattullo
Year: 2024
Topic(s):
Opioids & Substance Use See topic collection
Reference Links:       
7946
Naloxone for Opioid Overdose: Reply
Type: Journal Article
Authors: M. van Lemmen, J. Florian, Z. Li, M. van Velzen, E. van Dorp, M. Niesters, E. Sarton, E. Olofsen, R. van der Schrier, D. G. Strauss, A. Dahan
Year: 2024
Topic(s):
Opioids & Substance Use See topic collection
Reference Links:       
7948
Naloxone Prescribing and Education in Outpatient Pain Management and Palliative Care
Type: Journal Article
Authors: L. M. Coons, Gardea Hart, A. White, S. Summers
Year: 2021
Publication Place: England
Abstract:

Over the past two decades, opioid use and overdose have increased substantially. Naloxone, an opioid overdose reversal agent, has been one of many risk mitigation strategies for preventing mortality due to overdose. Most literature describing naloxone utilization has been about populations of illicit drug users and patients in hospitals, primary care, and pharmacies. There is limited information regarding naloxone prescribing and training for opioid users in specialty pain management clinics. Furthermore, there are no known publications concerning patients receiving palliative care services and overdose prevention. Pain and palliative care patients are commonly at risk of opioid overdose. In an interdisciplinary outpatient pain and palliative care clinic, pharmacists implemented naloxone prescribing and education. Eleven patients at increased risk for overdose were prescribed naloxone and educated on overdose risk factors, recognition, and management. Seven patients reported picking up their naloxone prescription from the pharmacy, and none reported using it within two weeks of the initial education. This intervention was deemed successful within the clinic, but small sample size and the pharmacist role may not be replicable within other pain and palliative care settings. It encourages further research of overdose risk and prevention in pain management and palliative care.

Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
7949
Naloxone prescribing to older adults in primary care
Type: Journal Article
Authors: Caroline D. Luther, Tamera D. Hughes, Stefanie P. Ferreri
Year: 2021
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
7950
Naloxone Telephone Outreach Program in an outpatient mental health clinic: A quality improvement project
Type: Journal Article
Authors: Jrywan N. Huang, Margit Gerardi, Olivia Yeargain, Tracy Senterfitt, Maria Saldiva
Year: 2023
Topic(s):
Healthcare Disparities See topic collection
7951
Naloxone use among overdose prevention trainees in New York City: A longitudinal cohort study
Type: Journal Article
Authors: A. Siegler, Z. Huxley-Reicher, L. Maldjian, R. Jordan, C. Oliver, A. Jakubowski, H. V. Kunins
Year: 2017
Publication Place: Ireland
Topic(s):
Opioids & Substance Use See topic collection
7954
Naltrexone (50 mg) Plus Psychotherapy in Alcohol-Dependent Patients: A Meta-Analysis of Randomized Controlled Trials
Type: Journal Article
Authors: Joanna Jarosz, Katarzyna Miernik, Maria Wachal, Jacek Walczak, Gunther Krumpl
Year: 2013
Topic(s):
Opioids & Substance Use See topic collection
7955
Naltrexone alters responses to social and physical warmth: Implications for social bonding
Type: Journal Article
Authors: Tristen K. Inagaki, Laura I. Hazlett, Carmen Andreescu
Year: 2019
Topic(s):
Opioids & Substance Use See topic collection
7956
Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy
Type: Journal Article
Authors: W. M. Liu, K. A. Scott, J. L. Dennis, E. Kaminska, A. J. Levett, A. G. Dalgleish
Year: 2016
Publication Place: Greece
Abstract: It has been reported that lower doses of the opioid antagonist naltrexone are able to reduce tumour growth by interfering with cell signalling as well as by modifying the immune system. We have evaluated the gene expression profile of a cancer cell line after treatment with low-dose naltrexone (LDN), and assessed the effect that adapting treatment schedules with LDN may have on enhancing efficacy. LDN had a selective impact on genes involved with cell cycle regulation and immune modulation. Similarly, the pro-apoptotic genes BAD and BIK1 were increased only after LDN. Continuous treatment with LDN had little effect on growth in different cell lines; however, altering the treatment schedule to include a phase of culture in the absence of drug following an initial round of LDN treatment, resulted in enhanced cell killing. Furthermore, cells pre-treated with LDN were more sensitive to the cytotoxic effects of a number of common chemotherapy agents. For example, priming HCT116 with LDN before treatment with oxaliplatin significantly increased cell killing to 49+/-7.0 vs. 14+/-2.4% in cultures where priming was not used. Interestingly, priming with NTX before oxaliplatin resulted in just 32+/-1.8% cell killing. Our data support further the idea that LDN possesses anticancer activity, which can be improved by modifying the treatment schedule.
Topic(s):
Opioids & Substance Use See topic collection
7957
Naltrexone Compared With Buprenorphine or Methadone in Pregnancy: A Systematic Review
Type: Journal Article
Authors: S. Atluru, A. K. Bruehlman, P. Vaughn, C. W. Schauberger, M. C. Smid
Year: 2024
Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
7958
Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals
Type: Journal Article
Authors: L. J. Nestor, L. M. Paterson, A. Murphy, J. McGonigle, C. Orban, L. Reed, E. Taylor, R. Flechais, D. Smith, E. T. Bullmore, K. D. Ersche, J. Suckling, R. Elliott, B. Deakin, I. Rabiner, Lingford Hughes, B. J. Sahakian, T. W. Robbins, D. J. Nutt, ICCAM Consortium
Year: 2019
Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
7959
Naltrexone for adolescent opioid use disorder: A bridge in the treatment gap?
Type: Journal Article
Authors: Matthew LaCasse, Joanna Quigley
Year: 2022
Topic(s):
Healthcare Disparities See topic collection